SRPX2

Across TCGA pan-cancer cohorts, SRPX2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SRPX2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SRPX2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SRPX2 is over-expressed in tumor, although a few such as KICH and KIRP show the opposite, repressed pattern.

COAD, LUAD, and KICH are the cancer types where SRPX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRPX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	IV	+4.810	<.001	12	view →
LUAD	Female	II,III,IV	+2.579	<.001	9	view →
KICH	Female	II,III,IV	−3.018	<.001	8	view →
READ	All	All	+2.845	.001	7	view →
LUSC	Male	II,III,IV	+1.515	<.001	7	view →
CHOL	Female	All	+4.393	<.001	5	view →
STAD	All	IV	+1.610	.002	5	view →
THCA	All	All	+0.550	.001	5	view →
LIHC	All	All	+0.630	.006	3	view →
KIRP	Male	All	−1.064	.014	1	view →
KIRC	All	All	−0.491	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SRPX2–COAD

Open the COAD breakdown →